Cover Image
市場調查報告書

AlgiPharma AS的產品平台分析

AlgiPharma AS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253797
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
AlgiPharma AS的產品平台分析 AlgiPharma AS - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 23 Pages
簡介

AlgiPharma AS是總公司設置於挪威的生物製藥企業,從事製藥產品的開發及商品化。其產品Oligo-G用於囊狀纖維化症,慢性的阻塞型肺疾,感染疾病,創傷,燒燙傷的治療上。其可破壞細菌的生物膜、治療過粘稠度症候群等,是深具未來性的藥劑。

本報告提供AlgiPharma AS 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,並彙整最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

AlgiPharma AS 基本資料

  • AlgiPharma AS 概要
  • 主要資訊
  • 企業資料

AlgiPharma AS :R&D概要

  • 主要的治療範圍

AlgiPharma AS :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

AlgiPharma AS :開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
  • 開發階段不明的產品
    • 開發階段不明的產品/聯合治療模式

AlgiPharma AS:藥物簡介

  • Oligomer G for Cystic Fibrosis
  • Oligomer G for COPD
  • Oligomer G for Wounds and Burns
  • Oligomer G for Pseudomonas Aeruginosa Infectious

AlgiPharma AS :開發平台分析

  • 各給藥途徑
  • 各分子類型

AlgiPharma AS :最新的開發平台資訊

AlgiPharma AS :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06936CDB

Summary

Global Markets Direct's, 'AlgiPharma AS - Product Pipeline Review - 2015', provides an overview of the AlgiPharma AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AlgiPharma AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AlgiPharma AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AlgiPharma AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AlgiPharma AS's pipeline products

Reasons to buy

  • Evaluate AlgiPharma AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AlgiPharma AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AlgiPharma AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AlgiPharma AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AlgiPharma AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AlgiPharma AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AlgiPharma AS Snapshot
    • AlgiPharma AS Overview
    • Key Information
    • Key Facts
  • AlgiPharma AS - Research and Development Overview
    • Key Therapeutic Areas
  • AlgiPharma AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AlgiPharma AS - Pipeline Products Glance
    • AlgiPharma AS - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • AlgiPharma AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • AlgiPharma AS - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • AlgiPharma AS - Drug Profiles
    • Oligomer G for Cystic Fibrosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligomer G for COPD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligomer G for Wounds and Burns
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligomer G for Pseudomonas Aeruginosa Infectious
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AlgiPharma AS - Pipeline Analysis
    • AlgiPharma AS - Pipeline Products by Route of Administration
    • AlgiPharma AS - Pipeline Products by Molecule Type
  • AlgiPharma AS - Recent Pipeline Updates
  • AlgiPharma AS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AlgiPharma AS, Key Information
  • AlgiPharma AS, Key Facts
  • AlgiPharma AS - Pipeline by Indication, 2015
  • AlgiPharma AS - Pipeline by Stage of Development, 2015
  • AlgiPharma AS - Monotherapy Products in Pipeline, 2015
  • AlgiPharma AS - Phase II, 2015
  • AlgiPharma AS - Phase I, 2015
  • AlgiPharma AS - Preclinical, 2015
  • AlgiPharma AS - Unknown, 2015
  • AlgiPharma AS - Pipeline by Route of Administration, 2015
  • AlgiPharma AS - Pipeline by Molecule Type, 2015
  • AlgiPharma AS - Recent Pipeline Updates, 2015

List of Figures

  • AlgiPharma AS - Pipeline by Top 10 Indication, 2015
  • AlgiPharma AS - Pipeline by Stage of Development, 2015
  • AlgiPharma AS - Monotherapy Products in Pipeline, 2015
  • AlgiPharma AS - Pipeline by Top 10 Molecule Type, 2015
Back to Top